Evidence map›Paper›PMID 37273996›Full record

ArticleInternational journal of bioprinting2023

3D bioprinting as a prospective therapeutic strategy for corneal limbal epithelial stem cell deficiency.

Qian Xue, Liang Ma, Hanyi Hu, Qi Li, Weiwei Wang, Huayong Yang, Bin Zhang

Abstract read
In one paragraph

Article in International journal of bioprinting, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Three-dimensional bioprinting in ophthalmic care.International journal of ophthalmology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qian XueState Key Laboratory of Fluid Power & Mechatronic Systems, Zhejiang University, Hangzhou, 310058, People's Republic of China.
Liang MaState Key Laboratory of Fluid Power & Mechatronic Systems, Zhejiang University, Hangzhou, 310058, People's Republic of China.
Hanyi HuSchool of Medicine, Zhejiang University, Hangzhou, 310058, People's Republic of China.
Qi LiState Key Laboratory of Fluid Power & Mechatronic Systems, Zhejiang University, Hangzhou, 310058, People's Republic of China.
Weiwei WangSchool of Medicine, Zhejiang University, Hangzhou, 310058, People's Republic of China.
Huayong YangState Key Laboratory of Fluid Power & Mechatronic Systems, Zhejiang University, Hangzhou, 310058, People's Republic of China.
Bin ZhangState Key Laboratory of Fluid Power & Mechatronic Systems, Zhejiang University, Hangzhou, 310058, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Limbal epithelial stem cells (LESCs) are responsible for the maintenance and repair of the corneal surface. Injuries and diseases of the eye may result in a vision condition called limbal stem cell deficiency (LSCD). Without limbal stem cells, the cornea becomes opaque, vascularized, and inflamed. Cultured LESC therapy as a treatment method was first described in 1997, and LESCs cultured from either patients or donors have been used to treat LSCD successfully. However, the main source of cornea for LSCD treatment is from donors, which are too few to meet the demand (less than 1:70 of cases). The global shortage of donor cornea promotes the need for studies exploring corneal limbus alternatives. Many problems still remain unresolved, such as original geometry reconstruction, corneal epithelial regeneration, and ocular optical function restoration. 3D bioprinting has garnered tremendous attention in recent years, and significant advances have been made in fabricating cell-laden scaffolds. These advancements could lead to a promising treatment for LSCD. It is possible that alternative limbus stem cells can be constructed using 3D printing, which, in corneal limbus regeneration, enables personalized corneal implants and fabrication of single- or multilayer corneal limbus equivalents with corneal limbal stem cells. In this review, the progress, applications, and limitations of the most influential works regarding current treatments of LESC deficiency are discussed. The advantages of 3D bioprinting are illustrated, and some first promising steps toward the creation of a functional cornea limbus with 3D bioprinting are discussed. Finally, insights into the prospects and technical challenges facing the future research of 3D bioprinting of corneal limbus alternatives

Indexed as

3D bioprintingCorneal limbusLimbal stem cell deficiencyRegenerative medicine

Identifiers

PMID37273996
PMCPMC10236339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.